Differential roles of regulatory T cells in acute respiratory infections

Milica Jovisic, … , Benjamin D. Singer, Luisa Morales-Nebreda


Acute respiratory infections trigger an inflammatory immune response with the goal of pathogen clearance; however, overexuberant inflammation causes tissue damage and impairs pulmonary function. CD4+FOXP3+ regulatory T cells (Tregs) interact with cells of both the innate and the adaptive immune system to limit acute pulmonary inflammation and promote its resolution. Tregs also provide tissue protection and coordinate lung tissue repair, facilitating a return to homeostatic pulmonary function. Here, we review Treg-mediated modulation of the host response to respiratory pathogens, focusing on mechanisms underlying how Tregs promote resolution of inflammation and repair of acute lung injury. We also discuss potential strategies to harness and optimize Tregs as a cellular therapy for patients with severe acute respiratory infection and discuss open questions in the field.

Find the latest version:

https://jci.me/170505/pdf
Differential roles of regulatory T cells in acute respiratory infections

Milica Jovisic,1,2 Nurbek Mambetsariev,3 Benjamin D. Singer,1,2,4,5 and Luisa Morales-Nebreda1,2

1Division of Pulmonary and Critical Care Medicine, Department of Medicine, 2Simpson Querrey Lung Institute for Translational Science, 3Division of Allergy and Immunology, Department of Medicine, 4Department of Biochemistry and Molecular Genetics, and 5Simpson Querrey Institute for Epigenetics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Introduction

The COVID-19 pandemic, generations of influenza epidemics and pandemics, and the rise of multidrug-resistant bacterial pneumonia have increased awareness of the burden of acute respiratory infections (1, 2). Even before the COVID-19 pandemic, pneumonia due to a broad spectrum of viral and bacterial pathogens caused almost 80% of deaths from infection in the United States (3–5). The most common pathogens identified in patients with severe pneumonia are viruses and bacteria armed with a versatile set of tools to overwhelm and escape the host immune response (6). In addition to SARS-CoV-2, viruses frequently implicated in causing severe pneumonia include influenza viruses, respiratory syncytial virus (RSV), and rhinovirus (6, 7). Common pathogens recovered in bacterial pneumonia vary by the locale of acquisition, particularly community versus hospital settings, and include Streptococcus pneumoniae (pneumococcus), Haemophilus influenzae, Staphylococcus aureus, Enterobacterales, and Pseudomonas aeruginosa (1). Severe pneumonia from any etiology can result in the acute respiratory distress syndrome (ARDS), a heterogeneous clinical syndrome characterized by severe inflammation and injury to the alveolar epithelium and endothelium that is associated with mortality rates approaching 40% (8, 9). Across pathogens, a common thread in the pathophysiology of ARDS induced by severe pneumonia is a dysregulation of the immune response, which leads to aberrant inflammatory tissue damage (10–14). A delicate balance between an appropriate host response (to clear the infection) and processes that resolve inflammation and repair lung damage (to promote subsequent recovery) is tightly regulated by an ensemble of complex regulatory mechanisms of the innate and adaptive immune systems.

Regulatory T cells (Tregs) are a subset of CD4+ T cells that express the FOXP3 transcription factor and have diverse and context-specific functions in promoting immune homeostasis by suppressing over-exuberant immune system activation under steady-state and stressed conditions in the lung and other organs (15). In addition to maintaining self-tolerance, data mostly from mice demonstrate that Tregs exert important pro-resolution functions in the innate and adaptive immune response to pathogens, including those infecting the respiratory tract (16) (Table 1). Recently, multiple groups have described novel Treg functions in mice, distinct from their immunosuppressive roles, in promoting tissue protection and repair of tissue damage in the lung, muscle, skin, and vascular endothelium (15, 17–30). Less is known about the specific role of Tregs in resolution, tissue protection, and repair in human lung disease, but investigators have detected Tregs in the alveolar spaces of patients with pneumonia and ARDS (18, 31, 32). In this Review, we use “tissue-protective” to refer to processes that mitigate ongoing injury by imparting resilience to damage; “repair” refers to active processes that lead to regeneration of injured tissue. While these processes are often conflated in studies of immune-mediated tissue injury, they are separable events that require experimental interventions at different time points to accurately investigate. Translation of Treg-based therapeutics that limit immune-mediated tissue injury and promote tissue protection and repair following respiratory infection will require a detailed understanding of Treg identity and function (33). Here, our goal is to review distinct domains of Treg function in the host response to respiratory infection and subsequent lung injury and discuss open questions in the field that should be addressed as Treg-based therapeutics move into translation.
Mechanisms of Treg development and function

Tregs exhibit robust expression of the high-affinity interleukin-2 (IL-2) receptor α subunit (CD25), and their generation and function are dependent on expression of the FOXP3 transcription factor (33). In vivo, Tregs can be classified into two main populations, thymus-derived Tregs (tTregs) and peripherally induced Tregs (pTregs), on the basis of their ontological origin. The tolerogenic role of tTregs is intricately linked to their development in the thymus; indeed, they arise from self-reactive thymocytes whose T cell receptor (TCR) recognizes self-antigen (34). Early events requiring the chromatin organizer SATB1 establish Treg-specific super-enhancer landscapes at the Foxp3 conserved noncoding sequence (CNS) 0 and other loci that are necessary for Treg development before induction of Foxp3 expression (35). Continuous TCR stimulation then activates transcription factors (e.g., nuclear factor-κB, nuclear factor of activated T cells, and forkhead box protein O) that directly bind to the promoter, CNS2, and CNS3 of the Foxp3 gene to induce its expression (36). Signaling through the IL-2 receptor maintains the Treg-defining DNA methylation landscape through recruitment of ten-eleven translocation (TET) enzymes to CNS2 (37, 38). Ultimately, Tregs depend on this peculiar epigenetic landscape for their development and lineage stability (33, 39). In contrast, pTregs lacking the lineage-stabilizing tTreg-type epigenetic landscape arise from naive CD4+ T cells that mainly recognize non-self-antigens in peripheral tissues in response to transforming growth factor-β (TGF-β) and IL-2 (36).

Mutations in the Foxp3 gene in mice result in the scurvy phenotype, which is characterized by a lymphoproliferative disorder and autoimmunity, including lymphocytic lung inflammation (40, 41). Similarly, human loss-of-function mutations in FOXP3 cause the immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, which manifests with various autoimmune phenomena secondary to loss of self-tolerance across tissues, including the lung (42, 43). Accordingly, dysregulated Treg function underlies numerous autoimmune diseases, graft-versus-host disease, and allograft rejection syndromes in which the Treg immunosuppressive role negatively regulates pathogenic immune responses to self-antigen (44, 45). These immunosuppressive functions are mediated in part by secretion of immunomodulatory cytokines, including IL-10 and TGF-β (46–48), expression of inhibitory surface receptors such as CTLA-4 and PD-1 (49, 50), and adenosine generation in Tregs highly expressing CD39 and CD73 (51, 52). Tregs specific for tumor antigen inhibit the host antitumor immune response against malignant cells, rendering them a target for cancer immunotherapies (53, 54).

Mature Tregs can be classified based on distinctive phenotypic and functional attributes (55). Resting, or central, Tregs (cTregs) express CC chemokine receptor 7 (CCR7) and the adhesion receptor CD62L, which allow them to recirculate through secondary lymphoid organs (56). Activated, or effector, Tregs (eTregs) exhibit more phenotypic and functional adaptability, as they can upregulate specific transcription factors, chemokine receptors, and effector molecules, paralleling effector CD4+ T cell responses and enabling suppression of context-specific immunity (56). With the advent of next-generation sequencing technologies, investigators have shown how this conceptual framework incompletely accounts for the plasticity and functional heterogeneity of Tregs in different anatomical niches — allowing the identification of distinctive tissue-specific Tregs in the lung and other organs (57).

Tregs suppress lung inflammation and promote resolution

As noted above, Tregs function to suppress excessive immune system activation and maintain immune homeostasis (15). Following acute lung injury due to a respiratory pathogen, an initial innate immune response leads to robust neutrophil recruitment
In addition to promoting macrophage efferocytosis of apoptotic cells, Treg-macrophage crosstalk modulates other functions of lung macrophages during the initiation and resolution of pulmonary inflammation and injury (reviewed in ref. 62). Coculture experiments using mouse Tregs and lipopolysaccharide-stimulated (LPS-stimulated) alveolar macrophages revealed that Tregs function to decrease macrophage TNF-α generation in a contact-dependent manner (18). Similar experiments using thioglycolate-induced peritoneal macrophages demonstrated that Tregs also promote macrophage generation of the pro-resolving yet potentially profibrotic cytokine TGF-β (18). In the mouse intratracheal LPS model of acute lung injury, Treg-mediated recovery is dependent on TGF-β (18). In contrast, genetic experiments revealed that Treg generation of another antiinflammatory cytokine, IL-10, appears to be dispensable for resolution in the LPS model (18), although, as noted above, Tregs may signal to alveolar macrophages to promote macrophage secretion of pro-resolving IL-10 (63). IL-22 is a cytokine of the IL-10 family that signals to fibroblasts and epithelial cells to promote pulmonary antiviral responses (64), and some severe lung infections have been linked to parallel defects in IL-22 and Treg function (65). Interestingly, experimental data in mice suggest that FOXP3 suppresses IL-22 production in Tregs but that Tregs promote T helper (Th) cell production of IL-22 (66). Finally, lipid mediators in the leukotriene B4/BLT1 pathway recruit Tregs to the alveolar space and promote neutrophil efferocytosis — the phagocytic clearance of dead and dying neutrophils — represents a key event in the resolution of lung inflammation. Tregs interact with resident and recruited alveolar macrophages to promote neutrophil efferocytosis and hasten recovery (18, 60) (Figure 1). Mechanistically, experiments in mice determined that Tregs generate IL-13 to stimulate lung macrophage production of IL-10, which signals via the VAV1/RAC1 signaling pathway in an autocrine manner to promote efferocytosis during resolution of lung inflammation (60). Activation of other Treg pathways that promote neutrophil efferocytosis following bacterial clearance could limit lung inflammation and expedite host recovery. Bronchoalveolar lavage–based (BAL-based) strategies to define the timing of pathogen clearance in patients with severe pneumonia may help determine the time window when pro-efferocytosis pathways can be safely induced without sacrificing pathogen-clearing immune system functions (61).

Figure 1. Mechanisms of Treg-mediated immunosuppression and resolution of lung inflammation. Tregs exert pleiotropic effects on innate (A) and adaptive (B) immune cells to dampen excessive alveolar inflammation and promote resolution following infection-induced lung inflammation and injury. (A) Tregs express the high-affinity IL-2 receptor and interact with other immune cell subsets, suppressing their activation and modulating their function. During resolution of lung inflammation, Tregs generate IL-13, signaling alveolar macrophages to secrete IL-10. Autocrine IL-10 then promotes macrophage efferocytosis of apoptotic neutrophils through activation of the VAV1/RAC1 signaling pathway and subsequent cytoskeleton remodeling to prevent excessive tissue damage. Tregs also promote a pro-resolution phenotype in macrophages by inhibiting TNF-α generation and inducing TGF-β secretion. IL-22 induction, possibly through a CD4+ Th cell intermediate, contributes to recovery and may be Treg dependent. (B) Tregs also dampen primary T cell responses to respiratory infections that include CD4+ Th cell responses, Th2 cells (and subsequent recruitment of eosinophils), CD8+ T cells, and γδ T cells, inhibiting excessive inflammation in response to pathogens. In contrast, Tregs may have a role in the generation of CD8+ memory cells, but their effect on individual compartments of the memory pool is unknown. Tregs also express surface molecules, such as CTLA-4, PD-1, CD39, and CD73, that inhibit inflammation, but the role of these molecules in responses to lung pathogens is unclear.
resolution of lung inflammation (67), suggesting that modulators of leukotriene function could promote Treg recruitment and function following lung infection. A detailed assessment of Treg-macrophage interactions and Treg-generated cytokine profiles in humans with lung infection will promote our understanding of how these dynamics modulate the immune response to drive outcomes in patients. For example, we performed serial sampling via BAL in mechanically ventilated patients with severe pneumonia to reveal complex T cell–macrophage interactions that were mediated by specific cytokine and chemokine signaling loops in COVID-19 (32, 68) and targetable in patients using a small-molecule inhibitor of calcium release–activated calcium channels (69).

The role of Tregs in modulating lung inflammation mediated by the adaptive immune system is context dependent. Antigen-specific Tregs generated following infection attenuate the immune response against the pathogen, limiting damage from inflammation but also potentially contributing to chronic infections in the lung and other organs (70–73). Following influenza infection, viral antigen–specific Tregs are generated and limit bystander CD4+ T cell responses (74). Specific requirements for viral antigens in the Treg response to virus-induced lung injury remain unclear. The timing of induction of Treg functions also affects the phenotype of the adaptive immune response. While Treg depletion early during human metapneumovirus infection inhibits priming of CD8+ T cell responses, late depletion is dispensable (75). In a mouse model of pneumococcal pneumonia, a subset of TNFR2-expressing Tregs dampens bacterial dissemination by inhibiting proinflammatory IL-17A secretion by γδ T cells (76). In RSV infection, Tregs inhibit virus-specific CD4+ and CD8+ T cell responses to prevent excessive inflammation and immunopathology, including eosinophil-mediated inflammation (77, 78). Treg suppressive function is further highlighted in influenza vaccination, during which vaccine-generated, antigen-specific Tregs attenuate the adaptive response to immunization, decreasing the protective effect of the inoculation (79). Interestingly, Tregs promote optimal CD8+ memory T cell responses following influenza infection that are protective following a secondary challenge (80). The effect of Tregs on the tissue-resident memory T cell (Trm) compartment in the lungs is not known, although type 1 regulatory T cells — an antigen-tolerizing, unconventional subset of Tregs — are required for maintenance of the Trm pool in the gastrointestinal tract (81).

Ultimately, promoting Treg functions that allow pathogen clearance by other immune system cells while limiting harmful tissue inflammation will augment host recovery from infection and lung injury. Although the optimal balance and timing of Treg immunosuppressive functions that limit and resolve inflammation remain undefined, it is encouraging that data from human Treg cellular therapy trials in graft-versus-host disease have not shown a signal indicating an increased risk of severe infection (82, 83). Going forward, optimization of beneficial immunosuppressive functions of Tregs, perhaps via ex vivo strategies discussed below, will facilitate their deployment in the clinical setting.

Tissue protection and repair following infection-induced lung injury

The respiratory tract is remarkably quiescent despite being continuously exposed to inhaled pathogens and air particles that challenge the homeostatic resilience mechanisms that maintain normal lung architecture and physiology (84, 85). Hence, during an over-exuberant stimulus (e.g., infection-induced ARDS) that disrupts tissue integrity and normal function, the lung must tightly balance cellular mechanisms that clear pathogens, preserve healthy tissue, and activate facultative cellular progenitors that regenerate damaged tissue (86). To exert these myriad functions, the lung is composed of distinctive cell populations within interdependent anatomical regions corresponding to epithelial, endothelial, and mesenchymal compartments (87) (Figure 2). In humans and mice, Tregs accumulate and expand in the alveolar space in response to injury (18–23, 25–27, 88). Aside from their capacity to resolve inflammation, Tregs establish intercellular circuits that orchestrate compartment-specific tissue protection and repair of the respiratory system.

In conjunction with alveolar epithelial type 1 (AT1) cells, alveolar epithelial type 2 (AT2) cells form a tight barrier that lines the alveolar epithelium. AT2 cells secrete surfactant to facilitate lung expansion and prevent atelectasis, absorb excess alveolar fluid through vectorial ion transport, and, in response to injury, exhibit stem/progenitor cell–like properties, including self-renewal capacity and transdifferentiation into AT1 cells to reconstitute the epithelial side of the alveolar gas-exchange barrier (85). In experimental inflammatory and non-inflammatory mouse models of lung injury and regenerative alveologenesis, Mock and colleagues demonstrated that Tregs expressing CD103 (αε integrin) promote AT2 cell proliferation (20) and that Treg depletion alters AT2 cell transcriptional profiles (24). Following on this observation, they went on to demonstrate that the epithelial growth factor keratinocyte growth factor (KGF) mediates Treg-specific enhancement of AT2 cell proliferation in mice (21). Many of these studies used diphtheria toxin to deplete Tregs in mice whose Tregs express the human diphtheria toxin receptor (89). In these mice, prolonged absence of Tregs leads to spontaneous inflammation and tissue injury, possibly confounding experiments designed to test specific tissue-protective and reparative Treg functions. Although the mouse epithelial growth factor receptor (EGFR) has low affinity for diphtheria toxin (90), subtle blockade of the mouse EGFR by diphtheria toxin could contribute to injury and dysregulated repair in these systems. In patients with ARDS, intravenous administration of KGF did not promote recovery and may have been harmful in a phase II randomized controlled trial (91). It remains possible, however, that lung Tregs programmed to overexpress KGF could promote epithelial repair via local and contextual cell-cell interactions that were not achieved by an intravenous infusion.

Production of growth factors such as the EGFR ligand family molecule amphiregulin (AREG) has emerged as a mechanism of Treg-mediated tolerance, tissue protection, and possibly active repair, in multiple tissue types, including the lung (23, 28, 92–97). Specifically, in a mouse model of intranasal influenza-induced lung injury, Arpaia and colleagues found that IL-18 and IL-33 signaling drives Treg production of AREG to maintain lung gas exchange function and barrier architecture, suggesting a tissue-protective and perhaps reparative role for Treg-derived AREG (23). The signaling and transcriptional pathways by which Tregs exert reparative functions in the lung are now beginning to be uncovered. NOTCH4 regulates IL-18–induced generation
Tregs reduce recruitment of bone marrow–derived collagen-producing cells by decreasing signaling along the CXCL12/CXCR4 axis to limit collagen deposition by bone marrow–derived collagen-producing cells. AT1 cell, alveolar epithelial type 1 cell; AT2 cell, alveolar epithelial type 2 cell.

Figure 2. Mechanisms of Treg-mediated lung parenchymal tissue protection and repair. Tregs exert distinct functions to provide tissue protection and promote repair of the epithelial, endothelial, and mesenchymal compartments following infection-induced lung injury. Following lung injury, for example from influenza A virus (IAV) infection, signals from activated immune cells and damaged epithelial cells (e.g., IL-18 and IL-33) bind to their receptors on Tregs and drive Treg production of pro-epithelial growth factors (e.g., AREG and KGF) that signal to epithelial and Col14α1+ mesenchymal cells to promote epithelial regeneration. NOTCH4 regulates this axis in Tregs. The role of Tregs in modulating the population of KRT8+ transitional epithelial cells—also known as pre-alveolar type 1 transitional cell state (PAT5), alveolar differentiation intermediate (ADI), damage-associated transient progenitors (DATPs), and intermediate alveolar epithelial cells (AECints)—remains unclear. Tregs also generate pro-endothelial growth factors such as VEGF that promote the regeneration of alveolar capillary endothelial cells (ECs), including those expressing carbonic anhydrase 4 (CAR4) and the endothelial tip cell markers VEGFR2, NRP1, and APLN. Tregs also decrease fibroproliferation by decreasing signaling along the CXCL12/CXCR4 axis to limit collagen deposition by bone marrow–derived collagen-producing cells. AT1 cell, alveolar epithelial type 1 cell; AT2 cell, alveolar epithelial type 2 cell.
TISSUE REPAIR

The role of Tregs in promoting vessel sprouting (angiogenesis) has been explored mostly in the context of tumor immunity and tissue-specific ischemic injury (103). Facciabene and colleagues reported that hypoxic intraperitoneal tumors upregulate CCL28 to recruitCCR10^+ Tregs (104). Once in the tumor microenvironment, these Tregs promote EC expansion through increased VEGFA expression. In a mouse model of type 2 diabetes mellitus–induced peripheral artery disease, Tregs facilitate de novo formation of blood vessels through release of AREG and IL-10 in an apelin-dependent manner (105). Finally, in the mouse lung, D’Alessio and colleagues demonstrated that Tregs were necessary to mediate lung angiogenesis, but the mechanisms by which Tregs exert this reparative function remain unclear (106).

Age is the predominant risk factor for lung diseases, including pneumonia, and is associated with progressive homeostatic aging — a lack of pro-homeostatic physiological reserves. Before the COVID-19 pandemic, influenza viruses caused up to 650,000 respiratory deaths per year worldwide, mostly in people over age 65 (107). Recently, the COVID-19 pandemic has highlighted the dramatic association between age and the severity of viral pneumonia–induced ARDS (108). Adaptive T cell immune competence wanes throughout the lifespan, as does the naïve T cell repertoire and T cell–specific protective and reparative functions (109, 110). Our group demonstrated in a mouse model of heterochronic adoptive Treg transfer that old Tregs exhibit a cell-autonomous impairment in their ability to promote resolution of lung inflammation or injury, respectively. In that study, lung Tregs in young adult mice upregulated AREG, among other reparative molecules, to a greater extent than lung Tregs from old mice following influenza infection. Age-related alterations in DNA methylation patterning are a core hallmark of aging (108), and in our study, genome-wide DNA methylation profiling revealed that age-related epigenetic alterations explained the loss of reparative transcriptional programs following influenza infection. Beyond the lung, a growing body of literature suggests that age-related Treg dysfunction affects other tissues and organs, including adipose tissue, skeletal muscle, and the nervous system (29, 111, 112). In addition to age, sex and gender are important biological and demographic variables, respectively, that are associated with differential risks from severe pneumonia, including due to SARS-CoV-2, with male sex and gender consistently demonstrating increased susceptibility (113–115). Experimental data in the mousemodel of pneumococcal pneumonia demonstrated that estrogen signaling promotes Treg-macrophage crosstalk to restrain macrophage proinflammatory responses (116). Going forward, a more detailed understanding of the cellular and molecular mechanisms underpinning age- and sex-related alterations in Treg phenotype and function will better inform the development of Treg-targeted or Treg-based immunotherapies that promote recovery from severe respiratory infections across populations.

Tregs as clinical immunotherapy

While few studies have leveraged Tregs as a cellular therapy for human lung diseases, proof-of-concept studies demonstrated the safety of Treg infusions in suppressing inflammation associated with autoreactive disorders, including type 1 diabetes mellitus, graft-versus-host disease, and organ allotransplantation (83, 117–122). Because of their pleiotropic beneficial effects on infection-related acute lung injury, approaches to administer Tregs as a pro-recovery therapy have gained momentum during the COVID-19 pandemic, with early-phase studies suggesting safety of allogeneic Treg infusions for patients with severe SARS-CoV-2 pneumonia (27, 123). Most human trials have used polyclonal autologous or allogeneic Tregs isolated from peripheral whole blood or umbilical cord blood via immunomagnetic systems or flow cytometry cell sorting (33, 124). These protocols usually involve ex vivo expansion of Tregs to generate sufficient numbers for infusion (up to 5 × 10^9 cells per dose, which typically take 2–5 weeks to generate in culture). The addition of compounds such as rapamycin that suppress conventional T cell growth while promoting growth of Tregs may enhance Treg purity during ex vivo expansion (125, 126). An important barrier to using ex vivo–expanded autologous Tregs for the treatment of severe acute lung injury is that critically ill patients are often not capable of providing sufficient blood or cells, and the acuity of pneumonia-induced ARDS limits the time window to wait for ex vivo Treg expansion. Hence, optimizing allogeneic Treg products and developing strategies that maximize the on-target efficacy and safety of limited numbers of infused Tregs represents an important goal for the field. Moreover, tailoring Treg cellular therapy to exploit specific immunosuppressive versus tissue-protective and reparative functions could benefit clinical contexts characterized by persistent inflammation or injury, respectively.

Advances in the fields of synthetic immunology, cytokine biology, immunopharmacology, and epigenome editing technologies have broadened the capacity to engineer Tregs with enhanced trafficking, specificity, context-specific function, survival, and stability (Figure 3). CCR4-expressing CD103^+ Tregs are important for lung-specific recruitment of Tregs, as CCR4–deficient Tregs have limited lung trafficking capabilities, resulting in pneumonitis (127). Expression of the T helper type 1–specifying (Th1-specifying) transcription factor T-BET in Tregs drives expression of the chemokine receptor CXCR3 to promote trafficking to sites of Th1-skewed inflammation (128). Engineered Tregs with specific homing programs could target their function to sites of Th1 inflammation such as the acutely infected and inflamed lung. Chimeric antigen receptor (CAR) Tregs have been developed as a therapeutic strategy in autoimmune disease (129–131). After collection of Tregs from healthy donors or ex vivo generation/expansion, Tregs can be engineered to express synthetic receptors such as CARs or specific TCRs to confer specificity and potentially enhance reparative function in the lung. As they are engineered for antigen specificity, CAR Tregs or those with modified TCRs have the potential to decrease the number of cells required for therapeutic efficacy. Additionally, CRISPR-based strategies to delete or modify the Treg TCR could limit unintended autoreactivity of transferred Tregs. Further studies are needed to test the applicability of engineered Tregs in the setting of respi-
Some evidence suggests that FOXP3+ cells exhibit plasticity in inflamed and damaged microenvironments, leading to loss of their suppressive functions and gain of proinflammatory effector functions (132). Hence, a period of ex vivo expansion provides an opportunity to pharmacologically modify Tregs in ways that support their functional stability with the potential to augment desirable antiinflammatory and pro-repair functions (33). Epigenetic modifiers that target histone deacetylases, DNA methyltransferases, and TET demethylases may stabilize Tregs before therapeutic infusion (19, 133-140). Experimental data suggest that aryl-hydrocarbon receptor ligands (141, 142) and cyclin-dependent kinase 8 (CDK8) and CDK19 inhibitors (143-145) also promote Treg identity and function. Applying these modifiers in a goal-driven fashion could optimize Treg lineage stability and function prior to infusion, limiting off-target effects and maximizing intended benefits.
Postinfusion strategies that enhance Treg stability and function may also promote on-target effects of therapeutically transferred Tregs. Tregs depend on signaling through the high-affinity IL-2 receptor α subunit (CD25) for their development (146, 147), and approaches to augment Treg function by administering exogenous IL-2 have been successful in inducing tolerance, for example, in a trial of patients with graft-versus-host disease (148). While IL-2 administration can have toxic effects — including venous thromboembolism, capillary leak, and activation of effector T cell responses due to the expression of variable-affinity IL-2 receptors on endothelial, T, and NK cells (149) — low-dose IL-2 administration was well tolerated in that trial. To mitigate the potential toxicities associated with higher-dose exogenous IL-2 administration, investigators have applied gene editing technologies to enhance the Treg specificity of IL-2 therapy. Transduction with an orthogonal IL-2 receptor that selectively responds to orthogonal IL-2 rather than native IL-2 could specifically expand and maintain the transferred Treg population without binding ECs or expanding effector T and NK cells (150, 151). Other engineered IL-2-based compounds, including IL-2-mutines, IL-2/anti-IL-2 immune complexes, PEGylated IL-2, and IL-2–CD25 fusion proteins, may also boost in vivo Treg pro-recovery survival and function while reducing off-target effects (152).

Open questions

A number of questions with translational relevance remain open in the field despite extensive investigation into the mechanisms of Treg function in the context of acute respiratory infection. Here, we highlight some of these questions and speculate on how to address them going forward.

How does this rare immune cell subset comprising only 5% to 20% of lung CD4+ T cells exert such a profound effect on lung protection and regeneration following injury? We hypothesize that temporally coordinated and spatially restricted Treg-specific inductive signals to key alveolar progenitor populations enable Tregs to exert a major impact on restoration of barrier function despite their rarity. Using single-cell RNA sequencing and lineage-tracing technologies, investigators have started to uncover the distinctive heterogeneity and cell-specific contribution of alveolar epithelial, mesenchymal, and endothelial cell subpopulations in lung regeneration (96, 98, 101, 102, 153–158). Future research can leverage systems biology approaches and spatial profiling technologies to investigate spatially coordinated gene expression between Tregs and KRT8+ transitional-state alveolar epithelial cells (also called pre-alveolar type 1 transitional cell state, alveolar differentiation intermediate, damage-associated transient progenitors, and intermediate alveolar epithelial cells), CAR4+ ECs, and Col14a1-expressing mesenchymal cells, potentially elucidating novel intercellular signaling and molecular pathways that drive lung repair. Mechanistically, the temporal aspect of different Treg functions can be investigated with a tamoxifen-inducible Cre recombinase system expressed from the Foxp3 locus that is already in wide use (159). This system also allows tracing of Foxp3+ cells to track lineage stability and resolve the spatial localization of Tregs (39).

What are the cues that promote homing of Tregs to the lung and elicit their pro-recovery functions? Extracellular matrix-driven (ECM-driven) mechanical signals influence immune cell migration and recruitment, including T cells (160), but how the local distribution of different ECM cellular components supports Treg accumulation and modulates Treg function during the inflammatory and fibroproliferative phases of lung injury remains unknown. Outside of CCR4+ and CXCR3-mediated trafficking discussed above (127, 128), Treg-intrinsic mechanisms that promote homing to the injured lung are largely undefined. Whether and how the Treg TCR controls the Treg response to lung infection and injury also persists as an unresolved issue. Adoptive transfer of polyclonal splenic Tregs is sufficient to promote recovery from ongoing lung injury in lymphocyte-deficient (Rag1−/−) and Treg-deficient (diphtheria toxin–treated Foxp3CreERT2) mice (18–20, 25). It remains unclear whether a specific clone emerges after the transferred cells traffic to the lung. In a pivotal study by Arpaia and colleagues, induced ablation of the TCR on Tregs did not hinder their ability to produce tissue-protective AREG (23). In contrast, Tregs require TCR specificity to promote tissue regeneration following acute injury in muscle and visceral adipose tissue (161, 162). Detailed assessment of the TCR clonotypes that emerge in experimental and human respiratory infection will improve our understanding of the role of antigen-specific Tregs in the immune response to respiratory infection.

Do subsets of Tregs with distinct pro-resolution and pro-repair functions exist, or do they emerge in specific contexts? While bulk adoptive transfer of splenic Tregs is sufficient to promote recovery from experimental acute lung injury, there may be preexisting subsets of Tregs with specialized pro-recovery functions or dynamic processes that result in the emergence of a pro-recovery Treg subset from an otherwise homogenous population (163, 164). Which of these possibilities drives recovery from lung infection–induced injury remains unclear. As discussed above, IL-18 and IL-33 appear to signal through their receptors to induce the generation of reparative molecules, including AREG and possibly other growth factors and mediators. Accordingly, the IL-18 receptor may mark a reparative Treg subset (23, 165). Similarly, the IL-33 receptor subunit ST2 may serve as a marker of a reparative Treg subset in mice (23, 28, 29, 163, 164, 166). Important differences in ST2 and AREG expression between mouse and human Tregs may complicate identification of a reparative Treg subset and translation of ST2+ AREG-expressing Tregs for therapeutic tissue protection and repair in patients (167). Moreover, the effects of IL-33 on Tregs are pleiotropic, enhancing their immunosuppressive function in the tumor and injured lung microenvironments (168–171). Finally, while AREG and KGF have garnered substantial attention as discussed above, other EGFR ligands and soluble growth factors may also promote lung repair. Treg subsets that preferentially generate these molecules — or spatially localize to lung niches that optimize the short-range function of Treg-derived soluble growth factors — remain to be fully defined. Going forward, single-cell profiling of the FOXP3+ cell population of the injured lung paired with spatial transcriptomics and proteomics will uncover heterogeneity and identify rare yet potentially potent cell subsets involved in distinct pro-recovery functions.

How does the ontogeny of Tregs influence their functional characteristics? While some markers (e.g., HELIOS and NRP1) may differentiate Tregs from pTregs in some settings, no known set of markers separates these cells by their developmental origin in all contexts (172–175). Functionally, pTregs and tTregs appear to occupy distinct immunological niches, with pTregs serving to...
maintain homeostasis at mucosal surfaces where they may regulate the microbiome to modulate the host response to influenza infection (176–181). Differentiating whether the Tregs that appear in the lung following injury derive from pTreg or tTreg origins is experimentally challenging. Mice with deletion of the Foxp3 locus CNS1 do not generate pTregs and could serve to identify the contribution of pTregs versus tTregs in experimental lung injury (182). Finally, pTregs and tTregs carry distinct DNA methylation patterns at CNS0 and CNS2 (35, 183), which could be used to understand the contribution of each subset responding to lung injury. The role of epigenetic modifiers in these subsets to differentially modulate their function in the context of lung injury remains unknown (184).

How can Tregs be optimized as a clinical immunotherapeutic strategy? As detailed above, therapeutic translation of Tregs for use in promoting resolution of inflammation and repair of tissue damage following lung infection remains in its infant stages. Generating sufficient numbers of Tregs on a time scale that is aligned to clinical reality remains a challenge; off-the-shelf preparations can be used (27, 123), and strategies such as treatment with rapamycin have shown promise in promoting Treg purity in culture (125, 126).

The potential for loss of FOXP3+ cell identity and conversion to a proinflammatory phenotype introduces additional difficulty to the standardization of individual doses and the limiting of immune-mediated toxicity. In the inflamed lung, Tregs must rewire their metabolism to adapt to the hypoxic and nutrient-depleted microenvironment of the injured alveolar space (185). We demonstrated that mitochondria-generated metabolites shape Treg function, potentially by altering their DNA methylation profile (186). Hence, strategies to stabilize Treg identity in the face of metabolic stress, such as treatment with modulators of DNA methylation, could enhance the efficacy and safety of Treg-based cellular therapy (19, 134–136). CAR Treg technology could also be used to further optimize infused Tregs by improving their specificity and trafficking to tissues of interest (187). Advances in preparation of Treg therapies — such as the optimal number of infused cells, requirement for antigen recognition, and appropriate timing of the infusion — will open avenues to address specific disease states.

Conclusions

Tregs exert diverse roles in regulating the immune response to respiratory infections, suppressing injurious inflammation during the primary antimicrobial response, and promoting repair and return to homeostatic conditions following the infection. To achieve the goal of restoring optimal lung function, Tregs affect multiple immune and nonimmune cell types, including neutrophils, macrophages, eosinophils, CD8+ and CD4+ T cells, and epithelial, endothelial, and mesenchymal cells. Dysregulation of this complex ensemble conducted by Tregs leads to increased inflammation, poor repair, and, ultimately, failed recovery from respiratory infections. Augmenting Treg responses is a potential therapeutic strategy for the treatment of severe acute respiratory infections that lead to substantial morbidity and mortality.

The relevance of Tregs in regulating the immune response to respiratory infections has been established mostly in mice. Yet there are important differences in the lung compartment anatomy and cellular heterogeneity between mice and humans (188, 189) that could hinder the interpretability and influence of translation-based discoveries in mice for human health. Future work will need to further delineate the mechanisms that contribute to Treg function in humans. Robust transcriptomic analysis of Tregs recruited to the lungs will help identify subsets more adept at specific roles currently attributed to Tregs in general. Subsequently, identifying signals that bias the Treg population toward these subsets will shed light on how to manipulate and optimize the Treg response to respiratory pathogens. Additional insights into the stabilization of Treg identity will further unlock their potential as a cellular therapy.

Author contributions

The order of the 2 co–first authors was determined on the basis of their contributions to the writing of the manuscript.

Acknowledgments

NM is supported by NIH award T32AI083216. BDS is supported by NIH awards R01HL149885, R01HL153122, P01HL154998, P01AG049665, and U19AI135964. LMN is supported by the Parker B. Francis Opportunity Award and NIH awards K08HL15935 and U19AI135964.

Address correspondence to: Benjamin D. Singer or Luisa Morales-Nebreda, Simpson Querrey, 5th Floor, 303 E. Superior Street, Chicago, Illinois 60611, USA. Email: benjamin-singer@northwestern.edu (BDS); Email: luisamorales@northwestern.edu (LMN).
The Journal of Clinical Investigation

**REVIEW SERIES: LUNG INFLAMMATORY INJURY AND TISSUE REPAIR**


